MTOR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Argani et al. (Argani et al., 2010) reported activation of the mTOR pathway in TFE-tRCC patients compared to ccRCCs, as shown by increased phosphorylation levels of the downstream mTOR target S6.